๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Thalidomide therapy for myelofibrosis with myeloid metaplasia

โœ Scribed by Deborah A. Thomas; Francis J. Giles; Maher Albitar; Jorge E. Cortes; Srdan Verstovsek; Stefan Faderl; Susan M. O'Brien; Guillermo Garcia-Manero; Michael J. Keating; Sherry Pierce; Jerome Zeldis; Hagop M. Kantarjian

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
299 KB
Volume
106
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Prognostic diversity among cytogenetic a
Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia
โœ Ayalew Tefferi; David Dingli; Chin-Yang Li; Gordon W. Dewald ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 88 KB

## Abstract ## BACKGROUND Approximately 30โ€“50% of patients with myelofibrosis with myeloid metaplasia (MMM) demonstrate detectable cytogenetic abnormalities, the prognostic value of which has not been completely defined by previous retrospective studies. The current prospective study addresses thi

Leukemogenic risk of hydroxyurea therapy
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
โœ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 417 KB ๐Ÿ‘ 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a

Dysregulation and overexpression of HMGA
Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia
โœ Joris Andrieux; Jean-Loup Demory; Brigitte Dupriez; Sabine Quief; Isabelle Plant ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 262 KB

Among cytogenetic studies of patients affected with myelofibrosis with myeloid metaplasia (MMM), a rare chronic myeloproliferative disorder, we found several reports of structural abnormalities of the long arm of chromosome 12. Two MMM patients had a balanced translocation involving 12q: t(4;12)(q32